SMARCA4 and neoplasm: In vivo studies confirmed these findings, demonstrating that BRG1 overexpression in A549 tumors enhanced gefitinib sensitivity and suppressed tumor growth, akin to the effects observed in gefitinib-treated NCI-H358 tumors.